IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer

(2021) Liyun Luo et al.   Nature Communications

A Possible Link of Genetic Variations in ER/IGF1R Pathway and Risk of Melanoma

(2020) Tze-An Yuan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

(2020) Mariusz L. Hartman et al.   Cells

Understanding IGF-II Action through Insights into Receptor Binding and Activation

(2020) Andrew J. Blyth et al.   Cells

Targeting Alterations in the RAF–MEK Pathway

(2019) Rona Yaeger et al.   Cancer Discovery

Resistance to MAPK inhibitors in melanoma involves activation of the IGF-1R-MEK5-Erk5 pathway

(2019) Lucía Benito-Jardón et al.   CANCER RESEARCH

iGEAK: an interactive gene expression analysis kit for seamless workflow using the R/shiny platform

(2019) Kwangmin Choi et al.   BMC GENOMICS

Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies

(2019) Stephen A. Luebker et al.   Frontiers in Oncology

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma

(2018) Javier Vaquero et al.   CLINICAL CANCER RESEARCH

BRAFGene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors

(2018) Camilla Stagni et al.   MOLECULAR CANCER THERAPEUTICS

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

(2018) Sunilkumar Kakadia et al.   OncoTargets and Therapy

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association

(2018) Michael J. Vido et al.   Cell Reports

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

(2017) Liang Cheng et al.   MODERN PATHOLOGY

Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds

(2017) Jie Ying Chan et al.   MOLECULAR CANCER THERAPEUTICS

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy

(2017) Michael P. Sanderson et al.   MOLECULAR CANCER THERAPEUTICS

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma

(2017) Aayoung Hong et al.   Cancer Discovery

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

(2017) Michele Milella et al.   Scientific Reports

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

(2016) Marieke I.G. Raaijmakers et al.   Oncotarget

Type I insulin-like growth factor receptor signaling in hematological malignancies

(2016) Deeksha Vishwamitra et al.   Oncotarget

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

(2015) Gatien Moriceau et al.   CANCER CELL

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

(2015) W. T. Iams et al.   CLINICAL CANCER RESEARCH

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

(2015) Douglas B. Johnson et al.   EUROPEAN JOURNAL OF CANCER

Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer

(2015) Hye-Young Min et al.   Molecular Cancer

A Tale of Two Receptors: Insulin and Insulin-Like Growth Factor Signaling in Cancer

(2014) D. Yee   CLINICAL CANCER RESEARCH

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

(2014) Douglas B. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

(2014) Richard J. Young et al.   Pigment Cell & Melanoma Research

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

(2014) Georgina V. Long et al.   Nature Communications

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models

(2013) S. A. Flanigan et al.   CLINICAL CANCER RESEARCH

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

Receptor tyrosine kinases in cancer escape from BRAF inhibitors

(2012) Roger S Lo   CELL RESEARCH

Clinical Significance of IGF1R Expression in Non–Small-Cell Lung Cancer

(2012) Makoto Nakagawa et al.   Clinical Lung Cancer

Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy

(2012) Cristina E Tognon et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Biochemical Characterization of Individual Human Glycosylated pro-Insulin-like Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with Cancer

(2012) Sameer A. Greenall et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R

(2011) Kerrington R. Molhoek et al.   MELANOMA RESEARCH

Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma

(2011) K. Tworkoski et al.   MOLECULAR CANCER RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insulin-like Growth Factor Receptor-1 (IGF-1R) Expression in Normal Breast, Proliferative Breast Lesions, and Breast Carcinoma

(2011) Rohit Bhargava et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Insulin Receptor (IR) Pathway Hyperactivity in IGF-IR Null Cells and Suppression of Downstream Growth Signaling Using the Dual IGF-IR/IR Inhibitor, BMS-754807

(2010) Joseph E. Dinchuk et al.   ENDOCRINOLOGY

Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

(2010) E. Buck et al.   MOLECULAR CANCER THERAPEUTICS

Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells

(2009) N. Eckstein et al.   CANCER RESEARCH

The MAPK pathway in melanoma

(2009) Leslie A Fecher et al.   CURRENT OPINION IN ONCOLOGY

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

(2009) J. M. Carboni et al.   MOLECULAR CANCER THERAPEUTICS